Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT02499328 |
TitleStudy to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck | 阶段
Phase 1, Phase 2
|
Date Added 2015-07-16 |
地点
Alabama, United States
California, United States Colorado, United States Florida, United States Indiana, United States Massachusetts, United States Michigan, United States Montana, United States New Jersey, United States Ohio, United States Texas, United States Virginia, United States Washington, United States 比利时 德国 意大利 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
AZD5069, AZD9150, MEDI4736, tremelimumab (treme) |
标签
MSS/ MMRp
|
| NCT ID NCT06107413 |
TitleStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | 阶段
第二阶段
|
Date Added 2023-10-30 |
地点
Arizona, United States
Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States 比利时 德国 以色列 日本 大韩民国 西班牙 台湾 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan |
标签
MSS/ MMRp
|
| NCT ID NCT05425940 |
TitleStudy of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) | 阶段
第三阶段
|
Date Added 2022-06-21 |
地点
Alabama, United States
Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States 澳大利亚 比利时 法国 德国 香港 Hungary 大韩民国 新西兰 波兰 葡萄牙 新加坡 西班牙 台湾 泰国 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq |
标签
MSS/ MMRp
|
| NCT ID NCT05784688 |
TitleStudy of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2023-03-27 |
地点
Texas, United States
Washington, United States 大韩民国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
TU2218 + Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT03835949 |
TitleStudy of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer | 阶段
第 1 阶段
|
Date Added 2019-02-11 |
地点
Alabama, United States
Arizona, United States California, United States Texas, United States |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Atezolizumab, TJ004309 |
标签
MSS/ MMRp
|
| NCT ID NCT05350917 |
TitleStudy of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy | 阶段
第二阶段
|
Date Added 2022-04-28 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Tislelizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03865082 |
TitleStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | 阶段
第二阶段
|
Date Added 2019-03-06 |
地点
Arizona, United States
California, United States Texas, United States |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Ipilimumab, Nivolumab, Tilsotolimod, Opdivo, Yervoy |
标签
MSS/ MMRp
|
| NCT ID NCT02869217 |
TitleStudy of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | 阶段
第 1 阶段
|
Date Added 2016-08-16 |
地点
加拿大
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Cyclophosphamide, Fludarabine, TBI-1301 |
标签
MSS/ MMRp
|
| NCT ID NCT03223779 |
TitleTAS-102 加放射疗法治疗结直肠癌肝转移患者肝脏的研究 | 阶段
第 1 阶段
|
Date Added 2017-07-21 |
地点
Massachusetts, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03711058 |
TitleStudy of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2018-10-18 |
地点
Maryland, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Copanlisib, Nivolumab |
标签
MSS/ MMRp
|
